EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FGF21 increases the sensitivity of hepatocellular carcinoma to sorafenib under hypoxia

Ting Zhang, Huiling Shi, Shihui Zhang, Qin Zhu, Mengyuan Qiu, Ashleigh T. Chitakunye, Hanyu Hong, Liaoxin Luo, Yujing Li, Qiuyu Sun, Xiaokun Li, Lin Cai

Malignancy Spectrum · 2024

DOI: 10.1002/msp2.20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malignancy Spectrum, 2024. Verfasst von Ting Zhang und 11 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Wenzhou Municipal Science and Technology Bureau.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a common disease in human history and one of the main causes of cancer‐related death. Insufficient oxygen supply in the tumor microenvironment forces cancer cells to survive in a mild hypoxia environment. Fibroblast growth factor 21 (FGF21), a member of the FGF family, has become the focus of public attention due to its outstanding achievements in diabetes and lipid lowering. However, the mechanism of FGF21 in HCC remains unclear.

Objective

The aims of this study were to clarify whether or not FGF21 could increase the sensitivity of HCC to sorafenib (SORA) under hypoxia and explore the possible mechanism.

Methods

In this study, by using 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2 H ‐tetrazolium bromide cell viability test, plate clone formation test, western blot analysis, Hoechst/propidium iodide double staining experiment, flow cytometry, quantitative reverse transcription polymerase chain reaction, and subcutaneous tumor transplantation in mice, we studied the effects of recombinant human FGF21 combined with SORA on hepatoma cells in vitro and in vivo. FGF21 could enhance the phosphorylation of mothers against decapentaplegic homolog 3 (Smad3) under anaerobic conditions. When combined with SORA, FGF21 could increase the sensitivity of hepatoma cells to SORA and inhibit the growth and migration of hepatoma cells.

Results

FGF21 may increase the sensitivity of HCC to SORA by enhancing the phosphorylation of Smad3 through the phosphatidylinositol 3‐kinase/protein kinase B pathway under hypoxia.

Conclusion

Our study suggested the possibility of combination therapy for SORA and FGF21 on HCC.

Förderung

  • National Natural Science Foundation of China
  • Wenzhou Municipal Science and Technology Bureau

Zitieren

APA

Zhang, T., Shi, H., Zhang, S., Zhu, Q., Qiu, M., Chitakunye, A. T., Hong, H., Luo, L., Li, Y., Sun, Q., Li, X., & Cai, L. (2024). FGF21 increases the sensitivity of hepatocellular carcinoma to sorafenib under hypoxia. Malignancy Spectrum. https://doi.org/10.1002/msp2.20

Vancouver

Zhang T, Shi H, Zhang S, Zhu Q, Qiu M, Chitakunye AT, et al. FGF21 increases the sensitivity of hepatocellular carcinoma to sorafenib under hypoxia. Malignancy Spectrum. 2024. doi:10.1002/msp2.20

BibTeX
@article{Zhang2024,
  author = {Zhang, Ting and Shi, Huiling and Zhang, Shihui and Zhu, Qin and Qiu, Mengyuan and Chitakunye, Ashleigh T. and Hong, Hanyu and Luo, Liaoxin and Li, Yujing and Sun, Qiuyu and Li, Xiaokun and Cai, Lin},
  title = {FGF21 increases the sensitivity of hepatocellular carcinoma to sorafenib under hypoxia},
  journal = {Malignancy Spectrum},
  year = {2024},
  doi = {10.1002/msp2.20}
}
Kostenlos starten →